The role of topotecan in treating small cell lung cancer: second-line treatment
- 1 August 2003
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 41, S3-S8
- https://doi.org/10.1016/s0169-5002(03)90519-8
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Topotecan as first-line therapy for small cell lung cancer.Lung Cancer, 2003
- Chemotherapy as treatment of primary and recurrent small cell lung cancerLung Cancer, 2001
- Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung CancerJournal of Clinical Oncology, 1999
- Activity of Topotecan, a New Topoisomerase I Inhibitor, Against Human Tumor Colony-Forming Units In VitroJNCI Journal of the National Cancer Institute, 1992
- Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients.Journal of Clinical Oncology, 1992
- Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.Journal of Clinical Oncology, 1992
- Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1991
- A phase II study evaluating CAVi (cyclophosphamide, adriamycin, vincristine) potentiated or not by amphotericin B entrapped into sonicated liposomes, as salvage therapy for small cell lung cancerLung Cancer, 1990
- Second line chemotherapy in small cell lung cancerLung Cancer, 1989
- Cisplatin and Etoposide as Second-Line Chemotherapy in Patients with Small Cell Lung CancerCancer Investigation, 1988